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A 55 year-old female presented with a twomonth history of obstruc-
tive urinary symptoms. Physical examination revealed a mass involving
the anterior vagina and urethra without clinically evident inguinal ade-
nopathy. A pelvic MRI demonstrated a 3.5 cm enhancing proximal ure-
thral mass with suspected invasion of the bladder neck and anterior
vagina. Initial staging CT scans did not show any evidence of adenopathy
or distant metastasis. Cystoscopic biopsy yielded squamous cell carcino-
ma. Anterior pelvic exenteration was planned but subsequently abortedIntroduction
Carcinoma of the female urethra is a rare neoplasm that accounts
for less than 0.1% of all cancer types in women (Johnson and O'Connell,
1983). A standard treatment regimen has yet to be established due to
the relative scarcity and variability of this neoplasm. The location and
clinical stage of the disease dictate the method(s) of treatment used.
In the past, distally located and early stage tumors had been managed
with surgery or single modality radiotherapy alone. However, when
singlemodality approaches have been used for female urethral carci-
noma, local recurrences ranged from 36 to 60% and three year survival
0–29% (Foens et al., 1991). Therefore, distal lesions not amenable to
surgical resection with negative margins are nowmanaged with exter-
nal beam radiation therapy followed by brachytherapy. Likewise,
proximally located and more advanced tumors often are treated in
a similar manner in an effort to preserve anatomy and maintain
urinary function.
The concurrent use of radiation therapy and chemotherapy for
female urethral carcinoma has led to improvements in local control,
systemic control and overall survival (Libby et al., 2010; Nicholson
et al., 2008). We describe the successful treatment of two patients
with squamous cell carcinoma of the female urethra, both treated
with external beam radiation therapy and concurrent chemothera-
py followed by low dose rate interstitial brachytherapy.agnuson),
vms.edu (M. Shaves).
-ND license .intraoperatively because of bilaterally enlarged pelvic lymph nodes. An
ileal conduit urinary diversion and bilateral pelvic lymph node sampling
was performed. Bilateral lymph node involvement was found on ﬁnal
pathology, yielding stage IV (cT3c or pN2M0) disease.
Postoperatively, the patient received radiation therapy with con-
current chemotherapy. The patient was treated with 4500 cGy of
external beam radiation therapy delivered to the pelvis with 18-MV
photons through a four-ﬁeld box arrangement. The inguinal lymph
nodes were supplemented to a total dose of 4500 cGy through electron
ﬁelds because of clinical enlargement. Following this, a low dose rate
iridium-192 interstitial implant delivered an additional 1500 cGy to
the urethral tumor. CT was used to develop the plan, but the patient
was treated prior to the advent of 3D planning, so makeshift planning
was constructed. The volume covered included the original tumor,
urethra and margin.
Cisplatin and 5-ﬂuorouracil (5-FU) were initiated on day 1 of
radiation therapy. Continuous intravenous infusion of 5-FU was
administered at 750 mg/m2 for 6 days (days 1–3 and 29–31, total
4500 mg/m2) and 60 mg/m2 of cisplatin on days 1 and 29.
Side effects included acute grade 3 dermatitis, grade 2 mucositis
and grade 1 hematologic toxicity (nadirs: WBC-3.0, Hgb-10.6, Plt-145).
The patient did not experience any GI toxicity and urinary toxicity was
minimal as the ileal conduit was placed prior to RT. The patient actually
increased urethral voiding during RT, likely from decreased tumor size.
Recurrent episodes of distal vaginal mucositis were observed for the
ﬁrst 5 years following treatment, though each episode resolved with
medication. The patient was free of recurrence at last follow up eval-
uation, 90 months after completing all treatment.Case 2
A 41-year old female presented with a one month history of
vaginal bleeding and pelvic pain. Pelvic examination revealed bleeding
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4 cm proximally from the meatus. Cystourethroscopy demonstrated
obliteration of the urethral lumen by the mass and a percutaneous
supra-pubic catheter was placed. Biopsy of the mass revealed invasive
squamous cell carcinoma. Pelvic MRI revealed a 3.5 cm long urethral
mass with invasion of the anterior vaginal wall without mucosal
involvement (stage T3N0M0). Staging CT scans and a bone scan did
not demonstrate regional nodal or distant metastatic disease.
The patient received 4500 cGy to the pelvis, including the ingui-
nal lymph nodes, with 18-MV photons through anterior and posterior
opposing ﬁelds. Two weeks after completing external beam radiation,
a low dose rate iridium-192 interstitial implant delivered an addi-
tional 2500 cGy to the urethral tumor over 46 h. The same protocol
of concurrent chemotherapy that was used in Case 1 was applied to
this patient.
The patient tolerated radiation therapy well and experienced only
grade 3 desquamation in the three weeks following treatment, with-
out any GI or urinary toxicities. The patient's post-treatment course
was complicated by persistent dysuria and distal vaginal pain. Pelvic
examination 7 months after treatment revealed a 2 cm ﬁrm area at
the distal urethral region. PET imaging showed intense activity in
the region of the posterior urethra and biopsy revealed benign ﬁbro-
muscular tissue with reactive ﬁbrosis. The patient developed soft
tissue necrosis of the distal anterior vagina 14 months after treat-
ment and was successfully treated with hyperbaric oxygen therapy.
At 23 months, she developed a urethral stricture requiring dilation,
though urinary symptoms are now well controlled with an alpha-
blocking agent. The patient was free of recurrence and asymptom-
atic at last follow up, 47 months after treatment.
Discussion
The rarity of female urethral carcinoma has resulted in a lack of
consensus on the optimal management. Likewise, the limited number
of cases has made it difﬁcult to prospectively evaluate the various
treatment approaches. The most common current management of
distally located lesions that are not amenable to complete surgical re-
section with negative margins is external beam radiotherapy fol-
lowed by brachytherapy (Grigsby and Herr, 1996). Patients with
proximally located lesions and more advanced disease require a mul-
tidisciplinary approach that includes radiation therapy, chemothera-
py and possibly surgery.
The clinical stage of the tumor has been shown to be the strongest
predictor of disease free survival rates (Gheiler et al., 1998). A study
by Gheiler et. al showed that in women with distal urethral cancer,
the 5-year disease free survival rate approached 90% whereas for
proximal urethral carcinoma the disease-free survival rate was 40%
(Gheiler et al., 1998). A similar study by Weghaupt et. al demon-
strated an overall 5-year survival rate of 71% for women with distal
urethral tumors and 50% for those with proximal urethral tumors
(Weghaupt et al., 1984). The greater likelihood of nodal involve-
ment seen in proximal lesions is the reason for the signiﬁcant disparity
in disease free survival rates in patients with proximal versus distal
tumors.
Many women with proximal urethral carcinoma remain asymp-
tomatic until their disease is relatively advanced, thereby increasing
the probability of nodal involvement. A study by Foens demonstrated
the importance of treating the inguinal nodes when they found that
only 1 in 10 (10%) patients who received inguinal irradiation devel-
oped groin failures whereas 13 of 25 (52%) patients who did not re-
ceive inguinal irradiation developed groin failures (Foens et al., 1991).
When conventional, single-modality management is used for ure-
thral carcinoma, local recurrences range from 23 to 60% (Dalbagni
et al., 2001; Foens et al., 1991; Garden et al., 1993). Foens et al. dem-
onstrated that the local failure rate for the group treated with surgery
alone was greater (60%) than the local failure rate for the groupstreated with radiation therapy alone (36%) or combined surgery with
radiation (25%). A study by Dalbagni et. al found that 15 of 20 (75%)
patients who underwent surgery alone had local failure while no
local recurrence was seen in ten patients who received neoadjuvant
radiation therapy before surgery (Dalbagni et al., 2001). These retro-
spective studies provide support that combined modality therapy
offers the highest likelihood of eradicating disease.
Multiple series have demonstrated that superior local and inguinal
control rates have been achieved with combined external beam and
interstitial irradiation (Johnson and O'Connell, 1983; Weghaupt et al.,
1984; Licht et al., 1995). Milosevic et al. was among the ﬁrst to establish
a signiﬁcant improvement in local control with the addition of inter-
stitial irradiation. This study demonstrated that patients treated with
external beam radiation followed by brachytherapy had a 77% local
control rate at 7 years compared to a 32% local control rate for patients
treated with external radiation alone (Milosevic et al., 2000). Further-
more, a series by Foens found that 8 of 14 (57%) patients treated with
combined radiation therapy were alive without disease at three years
compared with 2 of 7 (29%) patients treated with external beam thera-
py alone and 0 of 7 (0%) patients treated with brachytherapy alone
(Foens et al., 1991).
Overall, external beam therapy followed by interstitial brachy-
therapy in female urethral carcinoma has yielded 5-year disease-free
survival rates of 70–90% for early stage tumors and rates of 20–30%
for more advanced tumors (Forman and Licther, 1992). The disparity
in survival rates has led to the addition of concurrent chemotherapy
for proximal, higher stage lesions. A combination of radiation therapy
and chemotherapy using 5-ﬂurouracil and cisplatin has been shown
to provide effective treatment for locally advanced urethral carcinoma
in females (Hussein et al., 1990). A single institution study by Gheiler
demonstrated the beneﬁts of combination therapy, as 88% of patients
treated with RT and concurrent 5-FU/cisplatin were alive NED at ﬁve
years (Gheiler et al., 1998). This combination approach of radiation
therapy and multi-agent radiosensitizing chemotherapy improves
local and distant disease control.
While the patients in the report by Gheiler et al. and in our series
were treated with cisplatin and 5-FU, other chemotherapy regimens
also have been shown to be efﬁcacious in treating female urethral
carcinoma, including TIP (paclitaxel, ifosfamide and cisplatin) and
capecitabine and cisplatin (Libby et al., 2010; Nicholson et al., 2008).
In a case study by Nicholson et al., a patient with squamous cell
carcinoma of the female urethra was treated with the addition of
paclitaxel and ifosfamide to cisplatin, in a neoadjuvant fashion, prior
to cisplatin concurrently with radiation therapy. This regimen was
chosen based upon previous studies demonstrating response rates of
greater than 80% when taxanes and platinum (+/− ifosfamide) were
used to treat squamous cell cancers of the cervix (Buda et al., 2005).
In a case series by Libby et al., two patients with adenocarcinoma of
the female urethra were treated with cisplatin and capecitabine con-
currently with radiation therapy (Libby et al., 2010).
Tumor down-staging with neoadjuvant chemotherapy prior to
surgical resection may be considered an alternative to deﬁnitive che-
moradiation therapy. In a study by Milowsky et al., sequential chemo-
therapy with doxorubicin and gemcitabine (AG) followed by paclitaxel,
ifosfamide and cisplatin (TIP) resulted in a major response in 73% of
patients with metastatic or advanced transitional cell carcinoma of
the urothelium (Milowsky et al., 2009). The choice of surgery or con-
current chemoradiation for locoregional control should be based upon
which modality offers the highest likelihood of disease control and
maintenance of continence and sexual function.
Conclusion
Owing to its relative rarity, there are no standard treatment
guidelines for female urethral carcinoma, and many different ap-
proaches have been used. In tumors not amenable to complete
3W.J. Magnuson et al. / Gynecologic Oncology Reports 2 (2012) 1–3surgical resection, we recommend the combination of external beam
radiation, concurrent chemotherapy and consolidative interstitial
brachytherapy. This approach is well-tolerated and review of the
limited available literature demonstrates improved outcomes com-
pared to single modality therapy.
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Appendix A. Staging classiﬁcation
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
Ta Non-invasive papillary, polypoid or verrucous carcinoma
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades periurethral muscle
T3 Tumor invades anterior vaginal or bladder neck
T4 Tumor invades other adjacent organs
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in a single lymph node 2 cm. or less in greatest
dimensionN2 Metastasis in a single lymph node more than 2 cm. but not
more than 5 cm. in greatest dimension, or multiple lymph
nodes, none more than 5 cm. in greatest dimension
N3 Metastasis in a lymph node more than 5 cm. in greatest
dimension
Distant metastasis (M)
MX Presence of distant metastasis cannot be assessed
M0 No distant metastasis
N1 Distant metastasis
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